Visual registration, in which multiparametric MRI targets are translated onto real-time ultrasound images, combined with image fusion software may offer the highest detection rate of clinically significantly prostate cancer and thus could aid in risk stratification, according to a new study published in European Urology. Dr. Catalona commented to Renal & Urology News, “Cost is a big issue in the US, where MRI scans are far more expensive, and many insurance companies do not cover them unless the patient has had a prior negative biopsy but still has a rising PSA.”